Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory M Vercellotti

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Plos One|April 26, 2018
Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 inductionJohn D Belcher, Chunsheng Chen, Julia Nguyen, et al.
American Journal of Hematology|July 13, 2017
A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockadeAnna Solovey, Arif Somani, John D Belcher, et al.
Blood|August 12, 2022
A model of painful vaso-occlusive crisis in mice with sickle cell diseaseIryna I Khasabova, Joseph Juliette, Victoria M Rogness, et al.
Frontiers in Medicine|May 5, 2023
The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell diseaseJohn D Belcher, Selvaraj Nataraja, Fuad Abdulla, et al.
Cancer Research|October 15, 2013
Carbon monoxide expedites metabolic exhaustion to inhibit tumor growthBarbara Wegiel, David Gallo, Eva Csizmadia, et al.
Haematologica|June 1, 2019
A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell diseaseJames G McArthur, Niels Svenstrup, Chunsheng Chen, et al.
Blood|January 8, 2010
The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic miceRobert P Hebbel, Gregory M Vercellotti, Betty S Pace, et al.
Blood Advances|July 4, 2019
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemiaSarah Cooley, Fiona He, Veronika Bachanova, et al.
British Journal of Haematology|January 6, 2023
Sickle red blood cell-derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factorRan An, Yuncheng Man, Kevin Cheng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 12, 2015
Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802Shernan G Holtan, Michael R Verneris, Kirk R Schultz, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Plos One|April 26, 2018
Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 inductionJohn D Belcher, Chunsheng Chen, Julia Nguyen, et al.
American Journal of Hematology|July 13, 2017
A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockadeAnna Solovey, Arif Somani, John D Belcher, et al.
Blood|August 12, 2022
A model of painful vaso-occlusive crisis in mice with sickle cell diseaseIryna I Khasabova, Joseph Juliette, Victoria M Rogness, et al.
Frontiers in Medicine|May 5, 2023
The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell diseaseJohn D Belcher, Selvaraj Nataraja, Fuad Abdulla, et al.
Cancer Research|October 15, 2013
Carbon monoxide expedites metabolic exhaustion to inhibit tumor growthBarbara Wegiel, David Gallo, Eva Csizmadia, et al.
Haematologica|June 1, 2019
A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell diseaseJames G McArthur, Niels Svenstrup, Chunsheng Chen, et al.
Blood|January 8, 2010
The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic miceRobert P Hebbel, Gregory M Vercellotti, Betty S Pace, et al.
Blood Advances|July 4, 2019
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemiaSarah Cooley, Fiona He, Veronika Bachanova, et al.
British Journal of Haematology|January 6, 2023
Sickle red blood cell-derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factorRan An, Yuncheng Man, Kevin Cheng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 12, 2015
Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802Shernan G Holtan, Michael R Verneris, Kirk R Schultz, et al.
Pageof 11